NASDAQ:EYPT - Eyepoint Pharmaceuticals Stock Price, Forecast & News

Eyepoint Pharmaceuticals trades on the NASDAQ under the ticker symbol "EYPT."

Eyepoint Pharmaceuticals Inc (NASDAQ:EYPT) released its quarterly earnings data on Thursday, November, 7th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.14) by $0.01. The business earned $2.51 million during the quarter, compared to analyst estimates of $4.81 million. Eyepoint Pharmaceuticals had a negative net margin of 409.07% and a negative return on equity of 250.32%. View Eyepoint Pharmaceuticals' Earnings History.

Eyepoint Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Eyepoint Pharmaceuticals.

4 brokerages have issued 12 month price targets for Eyepoint Pharmaceuticals' shares. Their forecasts range from $4.00 to $5.00. On average, they expect Eyepoint Pharmaceuticals' share price to reach $4.38 in the next twelve months. This suggests a possible upside of 157.4% from the stock's current price. View Analyst Price Targets for Eyepoint Pharmaceuticals.

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyepoint Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Eyepoint Pharmaceuticals.

Media coverage about EYPT stock has been trending positive this week, InfoTrie reports. InfoTrie ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Eyepoint Pharmaceuticals earned a news sentiment score of 3.0 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for Eyepoint Pharmaceuticals.

Eyepoint Pharmaceuticals saw a decrease in short interest in December. As of December 31st, there was short interest totalling 8,490,000 shares, a decrease of 5.5% from the December 15th total of 8,980,000 shares. Based on an average trading volume of 570,600 shares, the short-interest ratio is presently 14.9 days. Currently, 13.0% of the shares of the company are short sold. View Eyepoint Pharmaceuticals' Current Options Chain.

Some companies that are related to Eyepoint Pharmaceuticals include Quanterix (QTRX), Fluidigm (FLDM), Harvard Bioscience (HBIO), HTG Molecular Diagnostics (HTGM), BioNano Genomics (BNGO), Arrayit (ARYC), Precipio (PRPO), Scientific Industries (SCND), Aethlon Medical (AEMD), Pressure Biosciences (PBIO) and PositiveID (PSID).

Based on aggregate information from My MarketBeat watchlists, some companies that other Eyepoint Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Synergy Pharmaceuticals (SGYP), Progenics Pharmaceuticals (PGNX), XOMA (XOMA), Opko Health (OPK), Catalyst Pharmaceuticals (CPRX), AcelRx Pharmaceuticals (ACRX), Alimera Sciences (ALIM), Novavax (NVAX) and BIOLINERX LTD/S (BLRX).

Shares of EYPT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of EYPT stock can currently be purchased for approximately $1.70.

Eyepoint Pharmaceuticals has a market capitalization of $183.80 million and generates $2.96 million in revenue each year. The company earns $-53,170,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Eyepoint Pharmaceuticals employs 55 workers across the globe.View Additional Information About Eyepoint Pharmaceuticals.

The official website for Eyepoint Pharmaceuticals is http://eyepointpharma.com/.

Eyepoint Pharmaceuticals' mailing address is 480 PLEASANT STREET SUITE B300, WATERTOWN MA, 02472. The company can be reached via phone at 833-393-7646 or via email at [email protected]